case based presentation neil mclean december 3, 2009
TRANSCRIPT
![Page 1: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/1.jpg)
Case based PresentationNeil McLean
December 3, 2009
![Page 2: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/2.jpg)
You are called for consult on Tower 14 and after thinking “Man I hate that floor” You arrive to find a 41 year old male who is 48 hours post allogenic hematopoietic stem cell transplant for CML. He is in obvious Respiratory distress on 90% Star Wars .
![Page 3: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/3.jpg)
![Page 4: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/4.jpg)
List the 3 phases of HSCT.
![Page 5: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/5.jpg)
List the 3 phases of HSCT.
Phase I: Pre-engraftment (0 – 30 days)
Phase II: Early post-engraftment (30 – 100 days)
Phase III: Late post-engraftment (> 100 days)
![Page 6: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/6.jpg)
List the 5 main pulmonary complications of BMT in the order of the phases in which they occur.
![Page 7: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/7.jpg)
• List the 5 main pulmonary complications of BMT in the order of the phases in which they occur.
1. Engraftment syndrome (Phase I)2. Diffuse alveolar hemorrhage (Phase I)3. Idiopathic pneumonia syndrome (Phase I – II)4. Bronchiolitis obliterans organizing pneumonia
(BOOP) (Phase I – II)5. Bronchiolitis obliterans (Phase II – III)
![Page 8: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/8.jpg)
![Page 9: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/9.jpg)
Occurs in 7 – 35% of HSCT recipients (autologous > allogeneic)
Characterized by fever, erythematous rash, diarrhea, renal impairment and diffuse pulmonary infiltrates (from capillary leak), and may lead to multi-organ dysfunction.
Occurs within 96h of engraftment (ANC > 500), with a median time of onset is 11 days post-transpant (4 – 25 days)
Coincides with neutrophil recovery and thought to be due to cytokine release from these neutrophils.
Diagnostic criteria:
1) Fever + evidence of pulmonary injury (hypoxemia or infiltrates) 2) absence of infection or cardiac dysfunction3) Occuring within 5 days of neutrophil engraftment.
Rapid clinical improvement with high-dose steroids
Mortality ~ 25%
![Page 10: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/10.jpg)
Incidence ~ 5% (autologous > allogeneic)
40% of all causes of HSCT-related respiratory failure admitted to ICU
Presents as dyspnea, fever, cough and hypoxemia, usually within 30 days of transplantation
Hemoptysis reported in less than 20%
CXR shows alveolar or interstitial infiltrates in middle and lower lung zones
HRCT shows bilateral ground glass infiltrates
Risk factors: Age > 40 Intensive chemotherapy before HSCT Total body irradiation WBC recovery GVHD
No association between PT/PTT/platelets and DAH
![Page 11: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/11.jpg)
• Diagnostic criteria
1. Evidence of pneumonitis
1. Absence of infection
1. Progressively bloodier return in BALs from separate subsegmental bronchi or > 20% hemosiderin-laden alveolar macrophages
• Restrospective studies show better outcomes with high-dose steroids (1 g methylpred for 3-5 days followed by a 2 – 4 week taper)
• Case reports of good outcomes with Factor VIIa
• Mortality ranges between 50 – 70%
• Most common cause of death – multiple organ failure and sepsis
![Page 12: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/12.jpg)
Clinical features of pneumonia without evidence of infection
Incidence ~ 10% (allogeneic > autologous)
Median time of onset is 21 – 65 days
Risk factors:
Old age Malignancy other than leukemia Pretransplant chemotherapy Total body irradiation GVHD CMV positive donor
Wide-ranging clinical spectrum from incidental radiographic abnormalities to ARDS
Pathogenesis poorly defined, likely implicates lung tissue injury, inflammation, and cytokine release.
![Page 13: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/13.jpg)
• Diagnostic criteria:
1. Evidence of widespread alveolar injury (signs and symptoms of pneumonia, multilobar infiltrates, and widening A-a gradient)
2. Absence of active infection on BAL
• Steroids are often used but have not been shown to be effective in largest studies
• Case reports show improved lung function following the use of etanercept.
• Overall mortality ~ 75%• One year survival ~ 15%• Hospital mortality for those requiring MV is > 95%
![Page 14: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/14.jpg)
Prevalence ~ 1.5% (allogeneic >> autologous)
Present as dyspnea, dry cough, and fever occuring between 1 and 3 months following HSCT
Imaging shows patchy airspace disease with ground glass attenuation and nodular opacities on CT
PFTs show a restrictive pattern with decreased DLCO, without airflow obstruction.
Diagnosis usually requires open lung biopsy.
80% of patients respond to to steroids with radiographic resolution within 1 to 3 months.
Case fatality in HSCT patients ~ 20%
![Page 15: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/15.jpg)
Incidence of ~ 3.5%
Inflammatory disease of the small airways occurring between 2 months and 9 years post-transplantation
Leads to progressive obstructive airway disease with no parenchymal involvement.
Most often present with dry cough, dyspnea and wheezing
PFTs show irreversible airway obstruction
CXR may show hyperinflation or be normal
Steroids usually ineffective
Chronic therapy with macrolides may slow the progression
5 year survival of HSCT patients is 10% with BO vs 40% w/o BO
![Page 16: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/16.jpg)
Which of the five main pulmonary complications of HSCT respond to steroids?
![Page 17: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/17.jpg)
Which of the five main pulmonary complications of HSCT respond to steroids?
1. Engraftment syndrome2. Diffuse alveolar hemmorhage3. BOOP
(IPS and BO do not)
![Page 18: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/18.jpg)
The patient is intubated and transferred to the ICU. On arrival you note that he is febrile and hypotensive
![Page 19: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/19.jpg)
![Page 20: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/20.jpg)
20% of all deaths post BMT are infection-related.
This includes the burden of respiratory failure requiring mechanical ventilation, a harbinger of poor outcome.
Immunosuppression makes BMT patients particularly prone to infection, including community-acquired, hospital-acquired and opportunistic organisms.
Current Opinion in Critical Care 2001, 7:362–366
![Page 21: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/21.jpg)
Gram negatives (esp. early)
Gram positives PJP Fungi
Candida spp- 40% mortality with candidemia; 90% with deep infections
Aspergillus spp Viral
CMV HSV VZV
Potential organisms:All of them…
![Page 22: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/22.jpg)
Lower risk in phase III
![Page 23: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/23.jpg)
ONCOLOGY AND CRITICAL CARE 0749-0704/
![Page 24: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/24.jpg)
Lung Urinary tract Skin/soft tissue Sinuses Vascular access devices GI (inc. esophagus)
![Page 25: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/25.jpg)
Hand washing! Isolation
“reverse” isolation, gowns/gloves/masks for visitors
Single rooms Negative pressure
![Page 26: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/26.jpg)
![Page 27: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/27.jpg)
![Page 28: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/28.jpg)
Antimicrobial Prophylaxis Acyclovir, Gancyclovir (allogenic HSCT) Fluconazole (allogenic HSCT) TMP/SMX
Aspergillus prophylaxis has been problematic, i.e. risk profile of amphotericin B
Other routine antimicrobial prophylaxis for febrile neutropenia not supported by IDSA.
![Page 29: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/29.jpg)
IDSA Guidelines, 2002
![Page 30: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/30.jpg)
![Page 31: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/31.jpg)
Prevent organ failure (due to SIRS) i.e. prevent certain death
Minimize drug adverse effects (from shotgun approach to antimicrobial therapy)
Prevent resistance Save a few bucks.
![Page 32: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/32.jpg)
Cytomegalovirus pneumonitis ? Unchecked viral proliferation in lung ? Donor T-cell response (“graft vs lung”) Gancyclovir may cause neutropenia, and prolonged
therapy may lead to resistance HHV6
Cofactor in CMV pneumonitis Respiratory Syncytial Virus Parainfluenza Virus 3 Influenza A-
Risk factor for pulmonary aspergillosis
![Page 33: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/33.jpg)
The patient is broadly covered with antibiotics, antivirals and antifungals. He is started on vasopressors. The nurse has placed a NG tube and is asking you if its ok to feed him
![Page 34: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/34.jpg)
Mucositis
GVHD
Medication induced diarrhea
Enteritis Typhlitis Infectious
![Page 35: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/35.jpg)
++ common especially with myeloablative chemo
If 2ndary to BMT, associate with worse clinical outcome
Nutrition TPN: used with allo BMT ( risk of mucositis) TPN maintains Wt but no effect on survival
Management Need adequate pain relief Palifermin: recombinant human keratinocytic
GF-1
J Support Oncol 2004;2:223-247
![Page 36: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/36.jpg)
Interventions for preventing oral mucositis for patients with cancer receiving treatment, Cochrane Review 2007 Amifostine: cytoprotective metabolite “Chinese medicine” Hydrolytic enzymes Ice chips
![Page 37: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/37.jpg)
Following allogenic HSCT, acute ~3-5wks Incidence 20 to 80% Donor T lymphocytes recognize the
histocompatibility Ag of host tissue as foreign
Median onset 19 days post transplantation
Risk Factor: HLA disparity Age
![Page 38: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/38.jpg)
• Skin:– Maculopapular rash, puritus
• Liver• GI:
– Diarrhea: • can > 10L/d, • Watery
– GI Bleeding– Abdo pain, Fever, N/V– Mucosal damage = Portal of entry for infection
• Immunosuppression
![Page 39: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/39.jpg)
Diagnosis Classic rash + diarrhea + bili in first 100
days post transplant Biopsy of skin, liver OR rectum
![Page 40: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/40.jpg)
Prevention: Immunosuppression after allo BMT to
decrease T-cell activation Cyclo. Tacro, MTX, steroids
Treatment Continue original immunosuppression 1-2: Topical steroids, low dose prednisone 3-4: High-dose methylpred
Response 50-80%
J Support Oncol 2004;2:223-247
![Page 41: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/41.jpg)
43% prevalence after allo HSCT Usually mild Causes
GVHD Infectious Colitis
Pseudomembranous: C. Difficile Viral: CMV, Rotavirus, Adenovirus, HSV, HZV
Typhlitis
![Page 42: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/42.jpg)
Typhlon = cecum Clostridial infection Complication of severe neutropenia post
chemo Superinfection may lead to necrotizing
inflammation of ileocecal region Sx: Abdo pain, fever, neutropenia
![Page 43: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/43.jpg)
Caused by EBV
Proliferation of engrafted B lymphocytes
Rare!
Mural infiltration
![Page 44: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/44.jpg)
Your labs come back and his LFT’s are elevated
![Page 45: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/45.jpg)
![Page 46: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/46.jpg)
What are the three major causes of liver dysfunction post HSCT?
![Page 47: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/47.jpg)
What are the three major causes of liver dysfunction post HSCT?
1. VOD (Phase I)2. Acute GVHD of the liver (Phase II)3. Viral hepatitis (Phase II)
![Page 48: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/48.jpg)
![Page 49: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/49.jpg)
• Reported in 20 – 50 % of patients following HSCT
• Arises from thrombosis to small central hepatic venules
• Due to endothelial damage by high-dose chemotherapy
• Usually develops within the first 21 days
• Presents as weight gain, tender hepatomegaly and jaundice (the latter may be delayed)
![Page 50: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/50.jpg)
• Diagnosis based on clinical picture and timecourse
• Portal dopplers show diminished or reversed portal blood flow
• Transjugular biopsy can be used to confirm the diagnosis but is rarely performed as there is still a risk of major bleeding.
• Management is supportive though there is some evidence for the use of alteplase + heparin, defibrotide, or antithrombin concentrates.
• Fatal in 25 – 50 % of patients
![Page 51: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/51.jpg)
• Rarely causes fulminant liver failure
• Usually occurs within the 1st three months post-HSCT (often predated by skin and GI tract involvement)
• Most often presents as an elevation in conjugated bilirubin and alkaline phosphatase.
• Treatment involves steroids and immunosuppressives
![Page 52: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/52.jpg)
Adenovirus, HSV, and herpes zoster can all cause fulminant liver failure in these patients
CMV may also cause hepatitis, but it is rarely severe.
![Page 53: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/53.jpg)
Your pt is now fully ventilated and supported hemodynamically and the nurse reports, he has had no urine output over the past 3 hours
![Page 54: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/54.jpg)
Related to chemotherapy (various mechanisms; see next slide)
Related to complications of therapy Intravascular volume depletion +/- ATN
Emesis, diarrhea, acute illness Sepsis Exacerbation of underlying renal disease
![Page 55: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/55.jpg)
![Page 56: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/56.jpg)
![Page 57: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/57.jpg)
Antibiotics: Ampho B Aminoglycosides Acyclovir
immunosuppressants: Cyclosporine FK 506
![Page 58: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/58.jpg)
“Be renal-protective…” i.e. optimize intravascular volume and renal
perfusion Minimize nephrotoxic drugs/contrast
![Page 59: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/59.jpg)
You are on rounds the next day when the patient develops seizures
![Page 60: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/60.jpg)
Metabolic encephalopathy Drug toxicity Infections Muscle weakness Cerebrovascular events (Seizures)
![Page 61: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/61.jpg)
Cause of death in 7% of HSCT pt
Risk Factors: High-dose chemo
Immunosuppressive therapy
GVHD
Thrombocytopenia
Crit Care Med 2006 Vol. 34, No. 9 (Suppl.)
![Page 62: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/62.jpg)
J Support Oncol 2004;2:223-247
• Change in MS and sz
• Dvp in 1st 2 months
• Other causes
• Hypoxemia
•Lytes
•Met Ac, sepsis
•Liver failure
•Meds
![Page 63: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/63.jpg)
Cyclosporin and FK506 Tremor, H/A, hallucinations, HTN Cortical blindness, sz, encephalopathy Generalized cerebelar dysfunction, hemiparesis,
quadriplegia
High-dose busulfan 10% have seizures, need prophylaxis
Steroid induced psychosis, myopathy
![Page 64: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/64.jpg)
More common in allo HSCT Causes:
Intracranial bleed Infarction: infectious ( aspergillus) and non
infectious (rare, DIC) Poor outcome, mortality 69% Same management, need to r/o infx
![Page 65: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/65.jpg)
Bacterial Strep, Listeria, Nocardia
Fungal Aspergillus: main cause of CNS infx, usually
dissemintated disease Zygomycetes, Candida
Virus CMV, HSV, Adenovirus, VZV, HHV6, JC virus
![Page 66: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/66.jpg)
Symptoms Meningeal signs May have no sx because
immunocompromised
CSF PCR useful for dx
Minimal abnormalities in CSF
![Page 67: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/67.jpg)
Polyneuropathies Usually 2dary to chemo
GBS like disorder Asc motor weakness, dysesthesias, cramps IVIG, steroids, plasmapharesis
Polymyositis Associated with chronic GVHD Proximal weakness, arthralgia, CK Dx: EMG, muscle biopsy
![Page 68: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/68.jpg)
![Page 69: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/69.jpg)
![Page 70: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/70.jpg)
A few hours later, this patient is on rocket fuel, CVVHDF, heavy sedation and he develops pulseless VTach. A code is run, but unfortunately you are not able to reestablish a pulse
![Page 71: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/71.jpg)
SPH case based presentation
![Page 72: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/72.jpg)
Price et al., Am J Respir Crit Care Med, 1998.
![Page 73: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/73.jpg)
Naeem et al., Bone Marrow Transplantation, 2006.
![Page 74: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/74.jpg)
Scales et al., Critical Care 2008.
![Page 75: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/75.jpg)
Price et al., Am J Respir Crit Care Med, 1998.
![Page 76: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/76.jpg)
Price et al., Am J Respir Crit Care Med, 1998.
![Page 77: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/77.jpg)
Naeem et al., Bone Marrow Transplantation, 2006.
![Page 78: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/78.jpg)
• FY2008/09:
14 admissionsICU Mortality: 42.86%Hospital Mortality: 42.86%APACHE II (IV) scores: 25 (90)HSMR: .7644
• FY2007/08:
25 admissionsICU mortality: 16.00%Hospital mortality: 28.00%APACHE II (IV) scores: 26 (90)HSMR: .4557
![Page 79: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/79.jpg)
• Since overall survival of transplant patients admitted to the ICU has been increasing over the past decades, it is not possible to easily determine whether admission to an ICU will be futile for any one individual patient.
• Decisions concerning which patients are appropriate for ICU care and how long to continue aggressive therapy are complex issues requiring significant deliberation.
![Page 80: Case based Presentation Neil McLean December 3, 2009](https://reader031.vdocuments.site/reader031/viewer/2022012916/56649d9e5503460f94a89263/html5/thumbnails/80.jpg)